Optimize Neurology Prior Authorizations with Waystar Clearinghouse Integration

For neurology practices and health systems, integrating Klivira's prior authorization automation with the Waystar Clearinghouse offers a strategic advantage in managing complex treatment approvals. This synergy addresses the unique demands of neurology PA workflows.

Neurology prior authorizations are notoriously complex, driven by high-cost specialty drugs, advanced diagnostics, and stringent payer criteria. Revenue cycle directors and prior authorization coordinators face the dual challenge of ensuring timely patient access while maintaining financial health. An integrated approach that leverages automation within your existing Waystar revenue cycle framework is essential to navigate these complexities efficiently.

The Intersection of Neurology PA and Waystar Clearinghouse Capabilities

Neurology practices manage a high volume of prior authorizations for critical treatments like MS disease-modifying therapies, CGRP migraine biologics, and advanced imaging. Waystar's robust clearinghouse and RCM capabilities are central to claims submission and revenue integrity. Klivira enhances this by automating the prior authorization process, ensuring that the necessary clinical documentation is prepared and submitted, reducing manual effort and potential delays within the Waystar ecosystem.

Common Prior Authorization Triggers in Neurology

MS Disease-Modifying Therapies (DMTs) such as ocrelizumab, natalizumab, and oral agents.
Alzheimer's Disease therapeutics, including anti-amyloid antibodies like lecanemab, requiring specific biomarker confirmation.
Migraine prevention biologics (CGRP monoclonal antibodies) and oral gepants.
Spinal Muscular Atrophy (SMA) and ALS treatments, including high-cost gene therapies.
Botox injections for chronic migraine, spasticity, and dystonia.
Advanced imaging studies like brain MRI, MR angiography, and amyloid PET scans.

Navigating Complex Documentation and Common Denial Reasons

Neurology prior authorizations often require extensive documentation, adhering to frameworks like AAN Practice Guidelines. Payers frequently demand specific details on diagnosis, disease severity (e.g., EDSS for MS), prior therapy trials, and biomarker confirmations (e.g., amyloid PET for Alzheimer's anti-amyloid antibodies). Common denial reasons include failure to meet step therapy requirements for MS DMTs or CGRP migraine prevention, or gaps in chronic migraine criteria for Botox. Klivira's platform is designed to streamline the collection and submission of this critical data.

Klivira's Automation for Neurology within the Waystar Workflow

Klivira integrates with your EMR to extract clinical data, applying AAN-guideline-aware step-therapy logic for MS and CGRP migraine prevention. This automation streamlines the generation of prior authorization requests, which can then flow efficiently through your Waystar Clearinghouse for payer submission. Our platform also supports the complex diagnostic-biomarker documentation for Alzheimer's anti-amyloid therapies and manages periodic re-authorizations for chronic neurology treatments, ensuring seamless continuity of care and revenue cycle operations.

Tangible Benefits for Neurology Practices

Accelerated patient access to critical MS DMTs, Alzheimer's therapies, and CGRP biologics.
Reduced administrative burden on PA coordinators through automated documentation and submission.
Improved clean claim rates and reduced denials by addressing common step therapy and documentation gaps proactively.
Enhanced revenue cycle predictability by minimizing delays in treatment initiation and re-authorization.
Streamlined management of ongoing MRI monitoring requirements for neurology drugs.

Frequently asked questions

How does Klivira integrate with Waystar for neurology prior authorizations?

Klivira integrates with your EMR to automate prior authorization requests. Once generated, these requests are prepared for efficient submission, often leveraging existing clearinghouse connections like Waystar to reach payers via X12 278, ePA portals, or other channels, streamlining the entire revenue cycle process.

What are the most challenging types of neurology PAs that Klivira addresses?

Klivira excels at managing complex neurology PAs, particularly for high-cost specialty drugs such as MS disease-modifying therapies, Alzheimer's anti-amyloid antibodies, CGRP migraine biologics, and advanced imaging. Our system is designed to handle the intricate documentation and step therapy requirements for these categories.

How does Klivira help with step therapy requirements common in neurology?

Klivira's platform incorporates intelligent logic that tracks payer-specific step therapy protocols, especially prevalent for MS DMTs and CGRP migraine prevention. It helps ensure that prior authorization requests include documentation of prior treatment failures or exceptions, aligning with AAN guidelines and payer policies to reduce denials.

Can Klivira manage re-authorizations for chronic neurology treatments?

Yes, Klivira provides robust workflow management for periodic re-authorizations. Many neurology drugs, like MS DMTs and Botox for chronic migraine, require ongoing approval. Our system tracks re-authorization dates and automates the preparation of necessary documentation to ensure continuity of care and revenue.

What EMR systems does Klivira integrate with to support neurology PA through Waystar?

Klivira offers broad integration capabilities with leading EMR systems via standards like SMART on FHIR. This allows for seamless extraction of clinical data to populate prior authorization requests, which then flow into your Waystar Clearinghouse for efficient payer submission, regardless of your specific EMR vendor.